In the past AIDS cholangiopathy had an extremely poor prognosis. It is now rarely fatal.
In this study, doctors from California assessed the survival of patients with AIDS cholangiopathy. They also investigated prognostic variables.
The team evaluated 94 patients with AIDS cholangiopathy at the San Francisco General Hospital, between 1983 and 2001.
They collected data on mortality status, demographic and clinical variables, and ERCP results using death certificates, chart review, and endoscopic reports.
|Opportunistic infection was an indicator of poor prognosis.|
|American Journal of Gastroenterology|
The doctors found that the median survival time from the diagnosis of AIDS and AIDS cholangiopathy was 23 and 9 months, respectively.
In addition, they determined that HAART significantly improved the mortality of patients with AIDS cholangiopathy.
The team determined that any opportunistic infection of the digestive tract, lung, eye, nervous system, skin, or systemic involvement at diagnosis was an indicator of poor prognosis.
They also found that patients with high serum ALP levels tended to have a shorter life expectancy than those with normal or slightly elevated serum ALP levels.
However, CD4 lymphocyte counts, type of cholangiopathy, and the performance of sphincterotomy were not correlated with patient survival.
Dr Wei-Fang Ko's team concluded, "HAART administration most likely accounts for the recent dramatic improvement in survival of patients with AIDS cholangiopathy".
"Underlying immunosuppressive status, reflected by the presence or history of any opportunistic infections, is associated with a worse outcome".
"Serum ALP levels might be a good clinical indicator for the prognosis of patients with AIDS cholangiopathy".